65,437 trials
COVID-19
Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR Positive Symptomatic Illness — 23; 17; 28; 24 Participants — p=0.212
Amyotrophic Lateral Sclerosis
Primary: Electromyographic (EMG) Responses (Rest) — 6.8; 21.6; 8.4; -6.1 % change compared to TMS alone
Obesity
Primary: Changes in Body Weight — -5.1; -6.2 kg
Work-Related Condition
Primary: Correction Officers' Knowledge at Baseline — 6.3 units on a scale
Tricuspid Valve Regurgitation
Primary: All-cause Mortality — 2 Participants
Influenza · Respiratory Tract Infections
Primary: Number of Index Patients Who Received Annual Influenza Vaccine — 6982; 6988; 6920; 6990 Participants
Heartburn
Primary: Symptom Frequency and Severity/Distress Scores From Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) (Overall) — 8.5; 5.2; 2.2; 1.0 score on a scale
Hematological Malignancies · Acute Lymphoblastic Leukemia (ALL) · Acute Myelogenous Leukemia (AML)
Primary: Time to Neutrophil Engraftment — 12; 22 days
HIV Prevention
Primary: The Safety Profile of the 25 mg Dapivirine Vaginal Ring-004, When Inserted at Monthly Intervals. Participants Attended RC at Monthly Visits (up to Max of Three Monthly…
Polycystic Ovary Syndrome
Primary: Mean Percent Body Weight Loss — -7.67 percentage of weight — p=<.001
Epilepsy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 77.2 percentage of participants
HIV-1 Infections
Primary: The Percentage of Women With the Composite Endpoint of Abnormal Safety Findings. — 23; 28; 28 Participants
Human Immunodeficiency Virus
Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants
Major Depressive Disorder
Primary: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) — -11.5; -14.1; -13.1 score on a scale — p=0.0050
Aortic Aneurysm Abdominal
Primary: Treatment Success Proportion — 0.917 Proportion of participants — p=0.006